CLINICAL TRIALS PROFILE FOR INSULIN

505(b)(2) Clinical Trials for Insulin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00151697 ↗	LANN-study: Lantus, Amaryl, Novorapid, Novomix Study	Completed	Rijnstate Hospital	Phase 3	2005-05-01	Many diabetics gain weight while on insulin therapy. In this study, we evaluate the efficacy of the combination of glimepiride and short-acting insulin on weight control and glucose control. In this study, 150 diabetics whose diabetic control is inadequate while on maximal oral treatment will be randomized to either the new combination treatment or twice daily injections with a mixture of short- and longacting insulin or once-daily injection with a basal insulin analog. The study will compare glucose control and weight gain during a year after randomisation between the three treatments.
OTC	NCT00169299 ↗	Herbal Alternatives for Menopause Symptoms (HALT Study)	Unknown status	National Center for Complementary and Integrative Health (NCCIH)	Phase 4	2001-06-01	Surveys indicate that 25 to 33% of women have moderate to severe menopausal symptoms including hot flashes, night sweats, and disturbed sleep. The treatment of choice in the medical community for these symptoms is hormone replacement therapy, which is estrogen and sometimes progestin. Many women also use over-the-counter herbal remedies. However, less is known about how well these products work, or their safety. Few have undergone the kind of rigorous testing required of prescription drugs and little is known about their long-term effectiveness in relieving symptoms. The purpose of this study is to compare several over-the-counter herbal remedies to hormone replacement therapy. Our primary aim is to look at the effects of these remedies on your self-reported menopausal symptoms. We will also be measuring their effects on other factors known to be affected by hormone replacement therapy: cholesterol, blood sugar, bone density, vaginal cell structure, and blood clotting.
OTC	NCT00169299 ↗	Herbal Alternatives for Menopause Symptoms (HALT Study)	Unknown status	National Institute on Aging (NIA)	Phase 4	2001-06-01	Surveys indicate that 25 to 33% of women have moderate to severe menopausal symptoms including hot flashes, night sweats, and disturbed sleep. The treatment of choice in the medical community for these symptoms is hormone replacement therapy, which is estrogen and sometimes progestin. Many women also use over-the-counter herbal remedies. However, less is known about how well these products work, or their safety. Few have undergone the kind of rigorous testing required of prescription drugs and little is known about their long-term effectiveness in relieving symptoms. The purpose of this study is to compare several over-the-counter herbal remedies to hormone replacement therapy. Our primary aim is to look at the effects of these remedies on your self-reported menopausal symptoms. We will also be measuring their effects on other factors known to be affected by hormone replacement therapy: cholesterol, blood sugar, bone density, vaginal cell structure, and blood clotting.
OTC	NCT00169299 ↗	Herbal Alternatives for Menopause Symptoms (HALT Study)	Unknown status	Group Health Cooperative	Phase 4	2001-06-01	Surveys indicate that 25 to 33% of women have moderate to severe menopausal symptoms including hot flashes, night sweats, and disturbed sleep. The treatment of choice in the medical community for these symptoms is hormone replacement therapy, which is estrogen and sometimes progestin. Many women also use over-the-counter herbal remedies. However, less is known about how well these products work, or their safety. Few have undergone the kind of rigorous testing required of prescription drugs and little is known about their long-term effectiveness in relieving symptoms. The purpose of this study is to compare several over-the-counter herbal remedies to hormone replacement therapy. Our primary aim is to look at the effects of these remedies on your self-reported menopausal symptoms. We will also be measuring their effects on other factors known to be affected by hormone replacement therapy: cholesterol, blood sugar, bone density, vaginal cell structure, and blood clotting.

All Clinical Trials for Insulin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000110 ↗	Influence of Diet and Endurance Running on Intramuscular Lipids Measured at 4.1 TESLA	Completed	National Center for Research Resources (NCRR)	N/A	1969-12-31	The purpose of this pilot investigation is to use 1 H Magnetic Resonance Spectroscopy (MRS) to 1) document the change in intra-muscular lipid stores (IML) before and after a prolonged bout of endurance running and, 2) determine the pattern (time course) of IML replenishment following an extremely low-fat diet (10% of energy from fat) and a moderate-fat diet (35% of energy from fat). Specifically, the study will evaluate the change in IML following a 2-hour training run and the recovery of IML in response to the post-exercise low-fat or moderate-fat diet in 10 endurance trained athletes who will consume both diets in a randomly assigned cross-over fashion. We hypothesize that IML will be depleted with prolonged endurance exercise, and that replenishment of IML will be impaired by an extremely low-fat diet compared to a moderate-fat diet. Results of this pilot study will be used to apply for extramural grant support from NIH or the US Armed Forces to investigate the effect of dietary fat on the health and performance of individuals performing heavy physical training. It is anticipated that this methodology could also be employed in obesity research to delineate, longitudinally, the reported cross-sectional relationships among IML stores, insulin resistance and obesity.
NCT00000159 ↗	Sorbinil Retinopathy Trial (SRT)	Completed	National Eye Institute (NEI)	Phase 3	1983-08-01	To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00000380 ↗	Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances	Completed	National Institute of Mental Health (NIMH)	N/A	1996-06-01	The purpose of this study is to examine the effects of giving growth hormone releasing hormone (GHRH) to treat sleep disorders in older men and in older women who are on estrogen replacement therapy (ERT). Many older men and women complain of sleep disturbances. GHRH has been used successfully to treat sleep disorders in young men and may help older men and women. 40 healthy older men and 40 healthy older women on ERT will receive either GHRH or an inactive placebo. An individual may be eligible for this study if he/she is a healthy older man or woman with sleep disturbances, and is on estrogen replacement therapy (women).
NCT00000380 ↗	Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances	Completed	University of Washington	N/A	1996-06-01	The purpose of this study is to examine the effects of giving growth hormone releasing hormone (GHRH) to treat sleep disorders in older men and in older women who are on estrogen replacement therapy (ERT). Many older men and women complain of sleep disturbances. GHRH has been used successfully to treat sleep disorders in young men and may help older men and women. 40 healthy older men and 40 healthy older women on ERT will receive either GHRH or an inactive placebo. An individual may be eligible for this study if he/she is a healthy older man or woman with sleep disturbances, and is on estrogen replacement therapy (women).

Clinical Trial Conditions for Insulin

Condition Name

Condition Name for Insulin
Intervention	Trials
Diabetes Mellitus, Type 2	709
Diabetes	601
Type 2 Diabetes Mellitus	394
Diabetes Mellitus, Type 1	367

Condition MeSH

Condition MeSH for Insulin
Intervention	Trials
Diabetes Mellitus	2438
Diabetes Mellitus, Type 2	1629
Diabetes Mellitus, Type 1	909
Insulin Resistance	562

Clinical Trial Locations for Insulin

Trials by Country

Trials by Country for Insulin
Location	Trials
China	886
Canada	839
Germany	655
India	539
United Kingdom	477

Trials by US State

Trials by US State for Insulin
Location	Trials
California	698
Texas	624
New York	485
Florida	437
Pennsylvania	371

Clinical Trial Progress for Insulin

Clinical Trial Phase

Clinical Trial Phase for Insulin
Clinical Trial Phase	Trials
PHASE4	90
PHASE3	51
PHASE2	70

Clinical Trial Status

Clinical Trial Status for Insulin
Clinical Trial Phase	Trials
Completed	3416
Recruiting	658
Unknown status	436

Clinical Trial Sponsors for Insulin

Sponsor Name

Sponsor Name for Insulin
Sponsor	Trials
Novo Nordisk A/S	568
Sanofi	269
Eli Lilly and Company	236

Sponsor Type

Sponsor Type for Insulin
Sponsor	Trials
Other	5744
Industry	2588
NIH	673

Insulin: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 28, 2025

Introduction

Insulin remains the cornerstone of diabetes management, specifically for Type 1 diabetes and advanced Type 2 cases. As the global prevalence of diabetes surges, driven by lifestyle changes and aging populations, the market for insulin and its innovative derivatives continues to expand. This analysis synthesizes recent clinical trial developments, current market dynamics, and future projections, equipping healthcare decision-makers, investors, and industry stakeholders with actionable insights.

---

Clinical Trials Update

Recent Advances and Ongoing Trials

Recent years have witnessed a robust pipeline of innovative insulin formulations and delivery methods. Several notable clinical trials have focused on enhancing insulin’s pharmacokinetics, reducing hypoglycemia risk, and improving patient adherence.

• Ultra-Long-Acting Insulins:
  Trials assessing ultra-long-acting insulins such as LY3209590 (Erlotinib) and Insulin Icodec, which promise once-weekly dosing, are progressing. For instance, the phase III trial for Insulin Icodec demonstrated comparable glycemic control to existing long-acting insulins with a favorable safety profile, potentially reducing injection frequency and improving adherence [1].

• Inhaled Insulin:
  Inhaled insulins like Afrezza have experienced renewed interest. Current phase III studies evaluate long-term safety, pulmonary effects, and patient quality of life. Crucially, trials comparing inhaled insulin with subcutaneous injections have shown comparable efficacy with improved patient satisfaction [2].

• Artificial Pancreas Systems:
  Several trials are testing closed-loop insulin delivery systems, combining continuous glucose monitoring (CGM) with automated insulin pumps. Recent phase II/III trials demonstrate improved glycemic variability and reduced hypoglycemic episodes, with some devices now nearing regulatory approval [3].

• Bio-Artificial Insulin Delivery Systems:
  Emerging research focuses on encapsulation technologies, such as implantable devices that sequester insulin-secreting cells. Early-phase trials indicate potential for sustained insulin release with minimal immune response [4].

Safety and Efficacy Trends

The trials highlight a consistent emphasis on reducing hypoglycemia, improving glycemic stability, and patient quality of life. Advances in insulin analogs aim to mimic physiological insulin profiles more closely, with some candidates exhibiting action profiles that reduce postprandial spikes and overnight hypoglycemia [5].

---

Market Analysis

Current Market Landscape

As of 2023, the global insulin market was valued at approximately $35 billion, with projections reaching $50 billion by 2028, growing at a CAGR of 7%. The primary drivers include:

• Rising Diabetes Prevalence:
  According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes in 2021, expected to surpass 700 million by 2045 [6].

• Insurance Coverage and Reimbursement Policies:
  Wider recognition of insulin’s life-saving role has led to improved reimbursement schemes, particularly in high-income countries, increasing patient access.

• Technological Innovations:
  Novel delivery systems, including inhalation and automated pumps, drive market segmentation and premium pricing.

Key Market Players

Major pharmaceutical firms, including Novo Nordisk, Eli Lilly, Sanofi, and emerging entrants in biosimilar and biotechnological segments, dominate the market. For instance, Novo Nordisk’s blockbuster insulins—NovoLog and Tresiba—account for significant market share, while the firm’s recent focus on smart insulin and artificial pancreas systems signifies strategic diversification [7].

Regulatory and Competitive Landscape

Regulatory agencies like the FDA and EMA have approved new insulin formulations and delivery devices that address unmet needs, such as reduced hypoglycemia and better patient tolerability. Competitive pressures push incumbents toward innovation, especially in biosimilars, which could erode traditional pricing models but expand access in lower-income regions.

Geographical Distribution

High-income markets (North America and Europe) lead in adoption of advanced insulin therapies, driven by healthcare infrastructure and reimbursement policies. Conversely, emerging markets in Asia and Africa experience rapid growth demand, often supplemented by biosimilar entries that lower costs and expand coverage.

---

Future Market Projections

Growth Drivers

Projected market growth hinges on several factors:

• Increasing Diabetes Epidemic:
  Continued demographic shifts and urbanization foster rising incidence rates.

• Innovative Therapies:
  The transition toward ultra-long-acting insulins and smart delivery systems is expected to capture increasing market share.

• Digital Health Integration:
  The convergence of insulin delivery with CGM and mobile health platforms will enhance patient adherence and therapeutic outcomes.

Innovations and Emerging Trends

• Next-Generation Biosimilars:
  Biosimilar insulins are anticipated to account for up to 30% of the market share by 2030, offering cost-effective alternatives.

• Personalized Insulin Regimens:
  Genetic and phenotypic profiling will enable tailored therapies, improving efficacy and reducing adverse effects.

• Alternative Delivery Methods:
  Non-invasive routes (transdermal, oral insulins) remain in early-stage development, promising future breakthroughs.

Market Risks and Challenges

• Regulatory Hurdles:
  New formulations, especially bioengineered devices, face rigorous approval pathways.

• Pricing and Reimbursement Dynamics:
  Cost-containment policies in various countries could impact revenue growth.

• Patient Adoption:
  Acceptance of novel devices depends on education, usability, and cost factors.

Forecast Summary

• 2023-2028:
  Compound annual growth rate (CAGR) of approximately 7%, driven by innovation, demographic trends, and increased access.

• 2030 and Beyond:
  The market could reach $60 billion, with significant shifts toward integrated digital-therapeutic platforms and biosimilars.

---

Key Takeaways

• Clinical Innovation Is Accelerating:
  The pipeline of ultra-long-acting, inhaled, and artificial pancreas systems promises enhanced glycemic control, reduced hypoglycemia, and improved patient compliance.

• Market Growth Outpaces Historical Rates:
  Driven by the diabetes epidemic, technological advances, and expanded access, the insulin market is poised for robust expansion.

• Regulatory Evolution Will Shape Market Dynamics:
  Approvals of biosimilars and novel delivery devices will influence pricing, competition, and patient access.

• Emerging Markets Represent High-Reward Opportunities:
  As biosimilar insulin availability increases and healthcare infrastructure improves, developing regions will present growth opportunities.

• Digital Health Integration Is Critical:
  Future insulin therapies will likely incorporate digital health components, enabling personalized, automated management.

---

FAQs

1. How might recent clinical trials impact insulin therapy standards?
Recent trials demonstrating the efficacy, safety, and convenience of ultra-long-acting insulins and artificial pancreas systems can shift standard-of-care towards more automated and less burdensome therapies, enhancing glycemic control and patient quality of life.

2. What factors are driving insulin market growth in emerging economies?
Growing diabetes prevalence, rising income levels, improved healthcare infrastructure, and the entry of biosimilar products lower costs, making insulin therapies more accessible.

3. Are biosimilar insulins changing current market dynamics?
Yes. Biosimilars offer cost-effective alternatives, pressuring established brands to innovate and adapt pricing strategies, and expanding access in cost-sensitive markets.

4. What role will digital health play in the future of insulin therapy?
Digital health tools, including connected insulin pens, CGM devices, and automated delivery systems, will enable personalized, real-time management, reducing complications and improving adherence.

5. When might oral insulin formulations become commercially available?
While early-stage research indicates promise, oral insulin is still in clinical trials with no confirmed commercial date. Significant scientific hurdles remain, but breakthroughs could occur within the next decade.

---

References

[1] Clinical trial data on Insulin Icodec – PharmaTrialsDatabase, 2022.
[2] Inhaled insulin efficacy study – Diabetes Care Journal, 2021.
[3] Artificial pancreas systems analysis – Journal of Diabetes Science & Technology, 2022.
[4] Encapsulation technology research – Advanced Drug Delivery Reviews, 2021.
[5] Pharmacokinetic characteristics of next-gen insulin analogs – Diabetes Reviews, 2022.
[6] International Diabetes Federation, “IDF Diabetes Atlas,” 2021.
[7] Market share and strategic focus of Novo Nordisk – company annual report, 2022.